In June 2025, Google Ads is set to revise its Healthcare and Medicines policy, specifically the Unapproved Substances section, to permit the promotion of melatonin products in regions beyond the United States and Canada. Advertisers will be able to market these products as long as they comply with local laws and regulations. The update also clarifies that any violations of the new policy won't result in immediate account suspension, as advertisers will be granted a minimum of seven days' notice before any potential suspension action is taken.
In June 2025, Google Ads will update the Unapproved Substances section of the Healthcare and Medicines policy, allowing melatonin promotion beyond the U.S. and Canada.
Advertisers may promote melatonin products in accordance with local laws and regulations as per the upcoming policy change in June 2025.
Violations of this policy will not lead to immediate account suspension without prior warning; a warning will be issued at least 7 days prior.
The updates are part of Google's continued efforts to adapt its advertising policies in response to evolving market regulations.
Collection
[
|
...
]